While documenting life on Hawaii’s Big Island, photographer Josh Cogan follows one man’s path toward reconnection—where food, ...

National Geographic photographer Josh Cogan captures the quiet power of Hawaii’s ocean life, revealing how resilience shows ...

On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

HK Innoen is accelerating the expansion of its portfolio in geriatric and metabolic diseases by launching full-scale development of a treatment for ...

CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada ...

The MarketWatch News Department was not involved in the creation of this content. -- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authorization is based on ...

Background Intravenous immunoglobulin (IVIg) is effective in many neuroinflammatory disorders but carries a risk of thromboembolic events (TEEs). Subcutaneous immunoglobulin (SCIg) is effective, but ...

Dealing with a CIDP diagnosis is complex enough without the added stress of understanding your health insurance. Whether you are newly diagnosed or managing the condition for years, a solid ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare but treatable condition. Although the symptoms — muscle weakness, numbness, tingling, and loss of coordination — can significantly ...

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC ...